Company profilePharmaceutical#661 of 1,318 in Pakistan1 DRAP alert

MEDIVET (PVT) LTD.

Pharmaceutical company · 15 brands · 14 molecules

Ranked #23 of 36 companies in Cardiac Therapy

15 registered products 12 pharmaceutical brands 14 distinct molecules 1 DRAP alert

Company overview

15
registered products
12
pharmaceutical brands
14
distinct molecules
2
therapeutic classes
1
DRAP alerts

MEDIVET (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 15 product registrations across 14 distinct molecules. Its portfolio is concentrated in Cardiac Therapy and Antineoplastics. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by MEDIVET

2 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Immunostimulants 1
Endocrine Hormone Therapy 1

Top molecules by brand count

Therapeutic classes

Cardiac Therapy · 1Antineoplastics · 1

Regulatory record

1 alert in the DRAP feed we track.

Risk of Meningioma with Medroxyprogesterone Acetate.
2025-07-09

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Pharmasol (Pvt) Ltd. holds 116 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant
Atco Pharma International (Pvt) Ltd holds 231 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
CCL Pharmaceuticals (Pvt.) Ltd. DML: 000052 holds 38 molecules not in this portfolio
AmiodaroneBupropionCalcium FolinateCarboplatinCeftazidimeCisplatin

Get the full profile for MEDIVET

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.